MA
NBIX icon

Montag & Associates’s Neurocrine Biosciences NBIX Stock Holding History

Montag & Associates’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.56K Sell
21
-2
-9% -$297 ﹤0.01% 829
2026
Q1 		$2.99K Buy
23
+2
+10% +$265 ﹤0.01% 819
2025
Q4 		$2.97K Buy
21
+1
+5% +$145 ﹤0.01% 843
2025
Q3 		$2.83K Buy
20
+6
+43% +$813 ﹤0.01% 877
2025
Q2 		$1.73K Buy
14
+5
+56% +$573 ﹤0.01% 864
2025
Q1 		$947 Buy
9
+1
+13% +$127 ﹤0.01% 957
2024
Q4 		$1.05K Buy
8
+2
+33% +$247 ﹤0.01% 947
2024
Q3 		$720 Hold
6
– – ﹤0.01% 1001
2024
Q2 		$860 Hold
6
– – ﹤0.01% 951
2024
Q1 		$824 Buy
+6
New +$819 ﹤0.01% 942

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Montag & Associates's NBIX Position: Q2 2026 in Review

Montag & Associates reduced its Neurocrine Biosciences (NBIX) stake by 8.7% in Q2 2026, selling an estimated $297 and leaving 21 shares worth $3.56K. The position accounts for ﹤0.01% of the portfolio, ranked #829.

Montag & Associates first reported a position in NBIX in Q1 2024 and has held it in 10 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Montag & Associates held 21 shares of Neurocrine Biosciences worth $3.56K as of Q2 2026.
  • Montag & Associates sold 2 Neurocrine Biosciences shares in Q2 2026, an estimated $297.
  • Neurocrine Biosciences made up ﹤0.01% of Montag & Associates's portfolio in Q2 2026, its #829 holding.
  • Montag & Associates first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 10 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Montag & Associates's 13F filing for Q2 2026, filed 5 Aug 2026.